Key Takeaways FDA alignment on CLS-AX for wet AMD and Phase 2b outcomes may boost revenues and market leadership upon approval. Global partnerships and SCS technology expansions could enhance international market presence and revenue streams.Read more
Key Takeaways Leading drug delivery technology, strong clinical results, and global partnerships could drive rapid adoption, robust licensing income, and significant revenue and margin expansion. Diversified pipeline and growing disease prevalence ensure long-term product launches, revenue diversification, and strong potential for transformative partnerships with next-generation therapy developers.Read more
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
